KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Shares Outstanding (Weighted Average) (2016 - 2025)

Moderna (MRNA) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $389.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 1.3% to $389.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $389.0 million, a 1.3% increase, with the full-year FY2025 number at $389.0 million, up 1.3% from a year prior.
  • Shares Outstanding (Weighted Average) was $389.0 million for Q4 2025 at Moderna, roughly flat from $388.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $403.0 million in Q4 2021 to a low of $381.0 million in Q3 2023.
  • A 5-year average of $390.5 million and a median of $388.0 million in 2025 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 13.31% in 2021, then fell 3.98% in 2023.
  • Moderna's Shares Outstanding (Weighted Average) stood at $403.0 million in 2021, then fell by 2.23% to $394.0 million in 2022, then fell by 3.05% to $382.0 million in 2023, then increased by 0.52% to $384.0 million in 2024, then rose by 1.3% to $389.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Shares Outstanding (Weighted Average) are $389.0 million (Q4 2025), $388.0 million (Q3 2025), and $388.0 million (Q2 2025).